The DDI Marker Studies Knowledgebase has been updated in April 2025 and is available in the DIDB Resource Center.
In this update, we have continued identifying substrates, inhibitors, and inducers for CYP enzymes, UGTs, and various transporters. A total of 54 compounds were characterized, including substates of CYP2C9, CYP2C19, CYP3A, OAT1, OAT3, OCT2, MATE1, MATE2-K, and UGTs, inhibitors of CYP1A2, CYP2C8, CYP2C9, 2C19, CYP2D6, CYP3A, P-gp, BCRP, OAT1, OAT3, OATP1B1, OATP1B3, and UGTs, and inducers of CYP3A. Four compounds were identified as sensitive substrates of CYP3A based on dedicated DDI studies or PBPK modeling with itraconazole or ketoconazole. No strong inhibitors or inducers were identified in this update. Regarding UGTs, 10 drugs were characterized as UGT substrates, and 2 as inhibitors, supported by DDI or PGx data.
To view a comprehensive list of additions and modifications, including new compounds and updates to existing entries, you may use the “Recent Update” column (Column AE) on the spreadsheet and select “yes.”
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.